Clinical Trials on Bowel; Stricture in Argentina

Total 88 results

Centro de Educación Medica e Investigaciones Clínicas...

Recruiting

Endoscopic Scoring System Utilization in Inflammatory Bowel Disease

Inflammatory Bowel Diseases

Argentina
Hospital Britanico

Unknown

Impact of Diet on Capsule Endoscopy

Small Bowel Disease

Argentina
Hospital Nacional Profesor Alejandro Posadas
Instituto Ecuatoriano de Enfermedades Digestivas; Hospital Nacional Cayetano...

Recruiting

Role of Information and Communication Technologies for Health Support in Inflammatory Bowel Diseases: The DAMASCO Trial (DAMASCO)

Quality of Life | Inflammatory Bowel Diseases | Knowledge, Attitudes, Practice | Treatment Adherence and Compliance

Argentina
University Hospital, Ghent

Completed

VeSpAR: Comparing Vessel-Sparing Anastomotic Repair and Transecting Anastomotic Repair in Isolated Short Bulbar Strictures. (VeSpAR)

Urologic Diseases | Surgery | Urethral Stricture

Belgium, United States, Argentina, China, Mexico, Portugal, Spain, United Kingdom
The Foundation for Orthopaedics and Regenerative...

Recruiting

Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intravenous Infusion for IBD

Inflammatory Bowel Diseases

Antigua and Barbuda, Argentina, Mexico
Hospital Italiano de Buenos Aires

Completed

Diet in Pediatric Crohn´s Disease Treated With Biologics

Crohn's Disease

Argentina
Takeda

Completed

A Study to Evaluate Disease Control, Treatment Patterns, Burden of Disease and Quality of Life in Participants With Moderate to Severe Inflammatory Bowel Disease (IBD) (RISE AR)

Crohn Disease | Colitis, Ulcerative | Inflammatory Bowel Disease

Argentina
Centro de Educación Medica e Investigaciones Clínicas...

Completed

Efficacy and Safety of Saccharomyces Boulardii in the Treatment of Small Intestinal Bacterial Overgrowth

Irritable Bowel Syndrome

Argentina
Hospital Britanico

Completed

Impact of Bacillus Clausii Administration on Irritable Bowel Syndrome Patients

Irritable Bowel Syndrome

Argentina
Hospital de Clinicas José de San Martín
SILVATEAM

Completed

Utility of the Administration of Chesnut and Quebracho Extract for Irritable Bowel Syndrome Diarrhea Predominant

Irritable Bowel Syndrome | Diarrhea

Argentina
La Fundacion Favaloro para la Investigacion y la...
Fundación de Ciencias Exactas - UNLP

Enrolling by invitation

ImpRovE underSTanding of Short bOwel syndRome in Latin-amErica (RESTORE)

Short Bowel Syndrome

Argentina
Takeda

Completed

A Study of Teduglutide (Revestive®) in Children, Teenagers and Adults With Short Bowel Disease

Short Bowel Syndrome

Argentina
Sanofi

Completed

Nolpitantium Besylate In Patients With Ulcerative Colitis a Double-Blind, Placebo Controlled Efficacy and Safety Study (NICE)

Ulcerative Colitis | Inflammatory Bowel Disease

Canada, Brazil, Russian Federation, Italy, Spain, Sweden, Estonia, Singapore, Belgium, Czech Republic, Argentina, Hungary, Chile, South Africa
Sahlgrenska University Hospital, Sweden
Hospital Universitario La Paz; Sahlgrenska University Hospital, Gothenburg,... and other collaborators

Recruiting

The Endoscopic Assesment of Intestinal Grafts (INTEGRATE)

Enteritis | Transplant; Complication, Rejection | Mucosal Inflammation | Transplant; Failure, Bowel | Transplant; Intestine

United States, Sweden, Argentina, Spain
Motif Bio

Completed

Phase 3 Study to Evaluate Safety and Efficacy of Iclaprim Versus Vancomycin for ABSSSI: REVIVE-2 (REVIVE-2)

Skin Structures and Soft Tissue Infections

United States, Argentina, Belgium, Croatia, Czechia, Estonia, Hungary, Portugal, Romania, Turkey
Takeda

Completed

Sub-optimal Response to Anti-Tumor Necrosis Factor's in Inflammatory Bowel Disease in Emerging Markets

Inflammatory Bowel Diseases | Crohn Disease | Colitis, Ulcerative

China, Korea, Republic of, Taiwan, Russian Federation, Turkey, Argentina, Colombia, Mexico, Saudi Arabia, Singapore
Janssen Research & Development, LLC

Terminated

A Study Evaluating Participants With Moderately to Severely Active Crohn's Disease (PRISM)

Crohn Disease

United States, Italy, Ukraine, Poland, Germany, Russian Federation, Argentina
Amgen

Recruiting

Long-term Safety and Efficacy of Efavaleukin Alfa in Participants With Moderately to Severely Active Ulcerative Colitis

Ulcerative Colitis

United States, Germany, Japan, Denmark, Romania, Argentina, Bulgaria, Hungary, Korea, Republic of, Mexico, Poland, Switzerland, Turkey
Genzyme, a Sanofi Company

Completed

Efficacy (Induction of Response/Remission) and Safety Study in Patients With Moderate to Severe Crohn's Disease

Crohn Disease

Switzerland, New Zealand, Canada, Australia, Brazil, Argentina, United Kingdom, Ukraine, Russian Federation
Trius Therapeutics LLC

Completed

TR-701 FA vs. Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infections. (ABSSSI)

Skin and Subcutaneous Tissue Bacterial Infections

United States, Argentina, Brazil, Canada, Czechia, Germany, Hungary, Latvia, Peru, Slovakia, Ukraine
Shire

Terminated

Efficacy and Safety Study of Ontamalimab as Induction Therapy in Participants With Moderate to Severe Crohn's Disease (CARMEN CD 306) (CARMEN CD 306)

Crohn's Disease

Spain, United States, Korea, Republic of, Hungary, Turkey, Belgium, Bulgaria, Argentina, Greece, New Zealand, Bosnia and Herzegovina, Colombia, Estonia, Ireland, Japan, Lebanon, Mexico, Portugal, Slovakia, Ukraine
Genzyme, a Sanofi Company

Terminated

Open-label Trial of Leukine in Active Crohn's Disease

Crohn Disease

Switzerland, United States, New Zealand, Canada, Australia, Brazil, United Kingdom, Ukraine, Russian Federation, Argentina
Shire

Terminated

Efficacy and Safety Study of Ontamalimab as Maintenance Treatment in Participants With Moderate to Severe Crohn's Disease (CARMEN CD 307) (CARMEN CD 307)

Crohn's Disease

Spain, United States, Korea, Republic of, Australia, Romania, Hungary, Israel, Italy, Croatia, Belgium, Bulgaria, Germany, Poland, Portugal, Argentina, United Kingdom, Greece, New Zealand, Austria, Bosnia and Herzegovina, Colombia, Eston... and more
Hoffmann-La Roche

Terminated

Open-Label Extension and Safety Study for Participants With Crohn's Disease Previously Enrolled in the Etrolizumab Phase III Study GA29144 (JUNIPER)

Crohn Disease

United States, Israel, Spain, United Kingdom, Canada, Australia, Austria, Czechia, France, Italy, Netherlands, New Zealand, Russian Federation, Belgium, Brazil, Korea, Republic of, Germany, Bulgaria, Croatia, Hungary, Poland, Ukraine and more
VectivBio AG

Active, not recruiting

Open-label Extension Trial to Evaluate the Long-term Safety of Apraglutide in Short Bowel Syndrome. (STARS extend)

Short Bowel Syndrome

United States, Belgium, United Kingdom, Korea, Republic of, Japan, Taiwan, Germany, France, Czechia, Hungary, Spain, Italy, Poland, Argentina, Denmark, Israel, Norway, Sweden
Hoffmann-La Roche

Completed

A Study to Assess Whether Etrolizumab is a Safe and Efficacious Treatment for Participants With Moderately to Severely Active Crohn's Disease (BERGAMOT)

Crohn Disease

United States, Israel, Spain, United Kingdom, Korea, Republic of, Canada, Australia, Austria, Czechia, France, Hungary, Italy, Netherlands, New Zealand, Russian Federation, Belgium, Brazil, Argentina, Bulgaria, Croatia, Germany, P... and more
Celgene

Active, not recruiting

Induction Study #1 of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn's Disease

Crohn Disease

United States, Italy, Germany, Russian Federation, Argentina, Australia, Belarus, Belgium, Bosnia and Herzegovina, Bulgaria, Canada, Chile, Croatia, Czechia, Denmark, Finland, France, Georgia, India, Ireland, Israel, Korea, Republic... and more
Eli Lilly and Company

Recruiting

A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease (VIVID-2)

Crohn's Disease

United States, Australia, Japan, India, Korea, Republic of, Canada, Turkey, Ukraine, Brazil, Mexico, Israel, Croatia, Hungary, Latvia, Lithuania, Serbia, China, Poland, Czechia, Slovakia, Switzerland, Russian Federation, Germany, Austria and more
AbbVie

Completed

A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Moderately to Severely Active Crohn's Disease Who Failed Prior Biologic Treatment

Crohn's Disease

United States, Argentina, Australia, Austria, Belarus, Belgium, Bosnia and Herzegovina, Bulgaria, Canada, Chile, China, Colombia, Croatia, Czechia, Denmark, Egypt, Estonia, France, Germany, Greece, Ireland, Israel, Italy, Korea, Republic... and more
Cubist Pharmaceuticals LLC
GlaxoSmithKline

Completed

Study Of Alvimopan Drug For Treatment Of Constipation Due To Prescription Pain Medication

Constipation | Bowel Dysfunction

United States, Netherlands, Spain, Taiwan, Peru, Philippines, France, United Kingdom, Canada, Czechia, Finland, Korea, Republic of, Hong Kong, Pakistan, Thailand, Italy, Argentina, Poland, Hungary, Germany, Russian Federation, South... and more
Melinta Therapeutics, Inc.

Completed

Delafloxacin vs Vancomycin and Aztreonam for the Treatment of Acute Bacterial Skin and Skin Structure Infections

Skin and Subcutaneous Tissue Bacterial Infections | Skin Structures and Soft Tissue Infections

United States, Argentina, Brazil, Bulgaria, Chile, Estonia, Georgia, Hungary, Korea, Republic of, Latvia, Mexico, Moldova, Republic of, Peru, Romania, Slovakia, Taiwan
Sanofi

Recruiting

Dose-finding Study of SAR443122 in Adult Participants With Ulcerative Colitis (RESOLUTE)

Colitis Ulcerative

Argentina, Chile, United States, China, Czechia, France, Germany, Hungary, India, Italy, Japan, Mexico, Netherlands, Poland, Spain, United Kingdom
Galapagos NV
Gilead Sciences

Completed

Filgotinib in the Induction and Maintenance of Remission in Adults With Moderately to Severely Active Crohn's Disease (DIVERSITY1)

Crohn's Disease

Hong Kong, United States, Netherlands, Belgium, France, Israel, Spain, Korea, Republic of, Taiwan, Germany, Australia, United Kingdom, Italy, India, Singapore, Portugal, Malaysia, New Zealand, Serbia, Ireland, Poland, Romania, Japan, ... and more
Galapagos NV
Gilead Sciences

Terminated

Filgotinib in Long-Term Extension Study of Adults With Crohn's Disease (DIVERSITYLTE)

Crohn's Disease

Hong Kong, United States, Netherlands, Belgium, Israel, Spain, Korea, Republic of, Taiwan, Germany, Australia, Italy, India, Singapore, Portugal, France, Malaysia, New Zealand, Ireland, Poland, Romania, Japan, Croatia, Iceland, United... and more
AbbVie

Completed

A Study of the Efficacy and Safety of Upadacitinib in Participants With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Conventional and/or Biologic Therapies (U-EXCEL)

Crohn's Disease

United States, Argentina, Australia, Austria, Belgium, Bosnia and Herzegovina, Brazil, Bulgaria, Canada, Chile, China, Colombia, Croatia, Czechia, Denmark, Egypt, Estonia, France, Germany, Greece, Hong Kong, Hungary, Ireland, Israel, Italy and more
AbbVie

Completed

A Study of the Efficacy and Safety of Risankizumab in Participants With Moderately to Severely Active Crohn's Disease

Crohn's Disease

United States, Argentina, Australia, Austria, Belarus, Belgium, Bosnia and Herzegovina, Brazil, Bulgaria, Canada, Chile, China, Colombia, Croatia, Czechia, Estonia, Germany, Greece, Hong Kong, Ireland, Israel, Italy, Japan, Korea, Republic... and more
Janssen Research & Development, LLC

Completed

A Study of Efficacy and Safety of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis (VEGA)

Colitis, Ulcerative

United States, Russian Federation, Australia, Poland, Germany, Brazil, Ukraine, Argentina, Mexico
AbbVie

Active, not recruiting

A Study of the Efficacy and Safety of Risankizumab in Participants With Crohn's Disease

Crohn's Disease

United States, Argentina, Australia, Austria, Belarus, Belgium, Bosnia and Herzegovina, Bulgaria, Canada, Chile, China, Colombia, Croatia, Czechia, Denmark, Egypt, Estonia, France, Germany, Greece, Hong Kong, Ireland, Israel, Italy, Japan, Korea, Republic... and more
Celgene

Recruiting

An Extension Study of Oral Ozanimod for Moderately to Severely Active Crohn's Disease

Crohn Disease

United States, Argentina, Australia, Belgium, Bosnia and Herzegovina, Bulgaria, Canada, Chile, Croatia, Czechia, Denmark, Finland, France, Germany, Ireland, Israel, Italy, Korea, Republic of, Latvia, Mexico, Moldova, Republic of, ... and more
Celgene

Recruiting

A Placebo-Controlled Study of Oral Ozanimod as Maintenance Therapy for Moderately to Severely Active Crohn's Disease

Crohn Disease

United States, Argentina, Australia, Belgium, Bosnia and Herzegovina, Bulgaria, Canada, Croatia, Czechia, Denmark, Finland, France, Germany, Ireland, Israel, Italy, Korea, Republic of, Latvia, Mexico, Moldova, Republic of, Poland, Romani... and more
AbbVie

Completed

A Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Biologic Therapy

Crohn's Disease

United States, Argentina, Australia, Austria, Belgium, Bosnia and Herzegovina, Brazil, Bulgaria, Canada, Chile, China, Colombia, Croatia, Czechia, Denmark, Egypt, Estonia, France, Germany, Greece, Hong Kong, Hungary, Ireland, Israel, Italy and more
Pfizer
Arena is a wholly owned subsidiary of Pfizer

Recruiting

A Study Evaluating the Efficacy and Safety of Oral Etrasimod in the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease (CULTIVATE)

Crohn's Disease

United States, Korea, Republic of, Netherlands, Colombia, Israel, Italy, Lebanon, Mexico, Poland, Spain, Turkey, Australia, Georgia, Czechia, Belgium, Germany, South Africa, Greece, Russian Federation, United Kingdom, Croatia, Serbia and more
Hoffmann-La Roche

Completed

A Study Comparing the Efficacy and Safety of Etrolizumab With Adalimumab and Placebo in Participants With Moderate to Severe Ulcerative Colitis (UC) in Participants Naive to Tumor Necrosis Factor (TNF) Inhibitors (HIBISCUS II)

Ulcerative Colitis

Australia, Czechia, France, Russian Federation, Malaysia, Bulgaria, United States, Croatia, Poland, Ukraine, Hungary, Colombia, New Zealand, Argentina, Turkey, Latvia, Brazil, Lithuania, Greece
AbbVie

Active, not recruiting

A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn's Disease Who Completed the Studies M14-431 or M14-433

Crohn's Disease

United States, Argentina, Australia, Austria, Belgium, Bosnia and Herzegovina, Brazil, Bulgaria, Canada, Chile, China, Colombia, Croatia, Czechia, Denmark, Egypt, Estonia, France, Germany, Greece, Hong Kong, Hungary, Ireland, Israel, Italy and more
Eli Lilly and Company

Completed

A Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease (VIVID-1)

Crohn's Disease

China, United States, Spain, Australia, Austria, Belgium, India, Japan, Korea, Republic of, Israel, Russian Federation, Canada, Hungary, Poland, Italy, Turkey, Switzerland, Germany, Brazil, Argentina, Latvia, Romania, Slovakia, Ukraine, Denmar... and more
Hoffmann-La Roche

Completed

A Study Comparing the Efficacy and Safety of Etrolizumab With Adalimumab and Placebo in Participants With Moderate to Severe Ulcerative Colitis (UC) in Participants Naive to Tumor Necrosis Factor (TNF) Inhibitors (HIBISCUS I)

Ulcerative Colitis

United States, Australia, Serbia, Hong Kong, Brazil, Bulgaria, Estonia, Poland, Russian Federation, Mexico, Ukraine, Argentina, France, Slovakia
Janssen Research & Development, LLC

Recruiting

A Long-term Extension Study of Ustekinumab in Pediatric Participants (UNITED)

Crohn Disease | Arthritis, Psoriatic | Colitis, Ulcerative

Belgium, France, United States, Hungary, Japan, United Kingdom, Germany, Poland, Argentina
VectivBio AG

Completed

Trial to Evaluate Efficacy and Safety of Apraglutide in SBS-IF (STARS)

Short Bowel Syndrome

United States, France, United Kingdom, Israel, Korea, Republic of, Germany, Japan, Taiwan, Sweden, Belgium, Spain, Czechia, Hungary, Norway, Italy, Argentina, Denmark, Poland
Sanofi
Regeneron Pharmaceuticals

Recruiting

A Study to Investigate the Efficacy and Safety of Dupilumab Therapy Compared With Placebo in Participants Aged ≥18 Years With Moderately to Severely Active Ulcerative Colitis With an Eosinophilic Phenotype (LIBERTY-UC SUCCEED (Study in UC for Clinical Efficacy Evaluation of Dupilumab))

Colitis Ulcerative

Argentina, Korea, Republic of, Mexico, United States, Canada, Chile, Japan, Puerto Rico, South Africa, Taiwan, Turkey
AbbVie

Active, not recruiting

Study Comparing Intravenous (IV)/Subcutaneous (SC) Risankizumab to IV/SC Ustekinumab to Assess Change in Crohn's Disease Activity Index (CDAI) in Adult Participants With Moderate to Severe Crohn's Disease (CD) (SEQUENCE)

Crohn's Disease (CD)

United States, Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, Chile, China, Czechia, France, Germany, Greece, Hungary, Israel, Italy, Korea, Republic of, Mexico, Netherlands, Poland, Romania, Russian Federation, Slo... and more

Clinical Trials on Bowel; Stricture in Argentina

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mongolia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations